BAM
PMVP icon

Blueshift Asset Management’s PMV Pharmaceuticals PMVP Stock Holding History

Blueshift Asset Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,635
Closed -$284K – 940
2022
Q1 		$284K Buy
+13,635
New +$241K 0.03% 632

Other funds holding PMVP

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Blueshift Asset Management's PMVP Position: Q2 2022 in Review

Blueshift Asset Management sold out of PMV Pharmaceuticals (PMVP) in Q2 2022, closing a stake of 13,635 shares — an estimated $284K sold.

Blueshift Asset Management first reported a position in PMVP in Q1 2022 and held it in 1 quarter. The position peaked at $284K in Q1 2022. 105 funds tracked by Wall St. Rank hold PMVP as of Q2 2022.

  • Blueshift Asset Management reported no remaining PMV Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Blueshift Asset Management sold 13,635 PMV Pharmaceuticals shares in Q2 2022, an estimated $284K.
  • Blueshift Asset Management first reported a position in PMV Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Blueshift Asset Management's PMV Pharmaceuticals position peaked at $284K in Q1 2022.
  • 105 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2022.

Based on Blueshift Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.